Effect of supplementation in treatment of polycystic ovary syndrome

Phase 3

• Conditions: Polycystic ovary syndrome.; Sclerocystic ovary syndrome Stein-Leventhal syndrome; E28.2

• Registration Number: IRCT201406075623N19
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 52

Inclusion Criteria

Patients with PCOS according to Rotterdam criteria
Women aged 18-40 years

Exclusion Criteria

Menopause
Consume zinc supplements in the last 3 months
Smokers
Pregnancy
History of diseases including diabetes, liver, kidney and CVD.
Thyroid disorders
Hyperprolactinemia
Cushing’s syndrome

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Insulin sensitivity. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.

Secondary Outcome Measures

Name	Time	Method
Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;VLDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.